Revenue Breakdown
Composition ()
No data
Revenue Streams
Incyte Corp (INCY) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is JAKAFI revenues, accounting for 57.9% of total sales, equivalent to $791.07M. Other significant revenue streams include OPZELURA revenues and JAKAVI product royalty revenues. Understanding this composition is critical for investors evaluating how INCY navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, Incyte Corp maintains a gross margin of 91.96%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 25.48%, while the net margin is 19.86%. These profitability ratios, combined with a Return on Equity (ROE) of 29.87%, provide a clear picture of how effectively INCY converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, INCY competes directly with industry leaders such as HCM and ROIV. With a market capitalization of $20.50B, it holds a leading position in the sector. When comparing efficiency, INCY's gross margin of 91.96% stands against HCM's 39.65% and ROIV's 64.98%. Such benchmarking helps identify whether Incyte Corp is trading at a premium or discount relative to its financial performance.
